Chapter 7. Life-Span Development of the Brain and Behavior

Follow us on Facebook or subscribe to our mailing list, to receive news updates. Learn more.


Links 41 - 60 of 5950

By Clay Risen William E. Pelham Jr., a child psychologist who challenged how his field approached attention deficit hyperactivity disorder in children, arguing for a therapy-based regimen that used drugs like Ritalin and Adderall as an optional supplement, died on Oct. 21 in Miami. He was 75. His son, William E. Pelham III, who is also a child psychologist, confirmed the death, in a hospital, but did not provide a cause. Dr. Pelham began his career in the mid-1970s, when the modern understanding of mental health was emerging and psychologists were only just beginning to understand A.D.H.D. — and with it a new generation of medication to treat it. Through the 1980s and ’90s, doctors and many parents embraced A.D.H.D. drugs like Ritalin and Adderall as miracle medications, though some, including Dr. Pelham, raised concerns about their efficacy and side effects. Dr. Pelham was not opposed to medication. He recognized that drugs were effective at rapidly addressing the symptoms of A.D.H.D., like fidgeting, impulsiveness and lack of concentration. But in a long string of studies and papers, he argued that for most children, behavioral therapy, combined with parental intervention techniques, should be the first line of attack, followed by low doses of drugs, if necessary. And yet, as he pointed out repeatedly, the reality was far different: The Centers for Disease Control and Prevention reported in 2016 that while six in 10 children diagnosed with A.D.H.D. were on medication, fewer than half received behavioral therapy. In one major study, which he published in 2016 along with Susan Murphy, a statistician at the University of Michigan, he demonstrated the importance of treatment sequencing — that behavioral therapy should come first, then medication. He and Dr. Murphy split a group of 146 children with A.D.H.D., from ages 5 to 12, into two groups. One group received a low dose of generic Ritalin; the other received nothing, but their parents were given instruction in behavioral-modification techniques. After two months, children from both groups who showed no improvement were arranged into four new groups: The children given generic Ritalin received either more medication or behavioral modification therapy, and the children given behavioral modification therapy received either more intense therapy or a dose of medication. © 2023 The New York Times Company

Keyword: ADHD; Drug Abuse
Link ID: 28984 - Posted: 11.04.2023

By Paula Span A year ago, the Food and Drug Administration announced new regulations allowing the sale of over-the-counter hearing aids and setting standards for their safety and effectiveness. That step — which was supposed to take three years but required five — portended cheaper, high-quality hearing aids that people with mild to moderate hearing loss could buy online or at local pharmacies and big stores. So how’s it going? It’s a mixed picture. Manufacturers and retailers have become serious about making hearing aids more accessible and affordable. Yet the O.T.C. market remains confusing, if not downright chaotic, for the mostly older consumers the new regulations were intended to help. The past year also brought renewed focus on the importance of treating hearing loss, which affects two-thirds of people over age 70. Researchers at Johns Hopkins University published the first randomized clinical trial showing that hearing aids could help reduce the pace of cognitive decline. Some background: In 2020, the influential Lancet Commission on Dementia Prevention, Intervention and Care identified hearing loss as the greatest potentially modifiable risk factor for dementia. Previous studies had demonstrated a link between hearing loss and cognitive decline, said Dr. Frank Lin, an otolaryngologist and epidemiologist at Johns Hopkins and lead author of the new research. “What remained unanswered was, If we treat hearing loss, does it actually reduce cognitive loss?” he said. The ACHIEVE study (for Aging and Cognitive Health Evaluation in Elders) showed that, at least for a particular group of older adults, it could. Of nearly 1,000 people ages 70 to 84 with untreated mild to moderate hearing loss, half received hearing assessments from audiologists, were fitted with midpriced hearing aids and were counseled on how to use them for several months. The control group participated in a health education program. Over three years, the study found that hearing-aid use had scant effect on healthy volunteers at low risk of cognitive loss. But among participants who were older and less affluent, hearing aids reduced the rate of cognitive decline by 48 percent, compared with the control group, a difference the researchers deemed “clinically meaningful.” © 2023 The New York Times Company

Keyword: Hearing; Alzheimers
Link ID: 28979 - Posted: 11.01.2023

By Carl Zimmer An international team of scientists has mapped the human brain in much finer resolution than ever before. The brain atlas, a $375 million effort started in 2017, has identified more than 3,300 types of brain cells, an order of magnitude more than was previously reported. The researchers have only a dim notion of what the newly discovered cells do. The results were described in 21 papers published on Thursday in Science and several other journals. Ed Lein, a neuroscientist at the Allen Institute for Brain Science in Seattle who led five of the studies, said that the findings were made possible by new technologies that allowed the researchers to probe millions of human brain cells collected from biopsied tissue or cadavers. “It really shows what can be done now,” Dr. Lein said. “It opens up a whole new era of human neuroscience.” Still, Dr. Lein said that the atlas was just a first draft. He and his colleagues have only sampled a tiny fraction of the 170 billion cells estimated to make up the human brain, and future surveys will certainly uncover more cell types, he said. Biologists first noticed in the 1800s that the brain was made up of different kinds of cells. In the 1830s, the Czech scientist Jan Purkinje discovered that some brain cells had remarkably dense explosions of branches. Purkinje cells, as they are now known, are essential for fine-tuning our muscle movements. Later generations developed techniques to make other cell types visible under a microscope. In the retina, for instance, researchers found cylindrical “cone cells” that capture light. By the early 2000s, researchers had found more than 60 types of neurons in the retina alone. They were left to wonder just how many kinds of cells were lurking in the deeper recesses of the brain, which are far harder to study. © 2023 The New York Times Company

Keyword: Brain imaging; Development of the Brain
Link ID: 28963 - Posted: 10.14.2023

By Laura Sanders A new look at the human brain is beginning to reveal the inner lives of its cellular residents. The human brain holds a dizzying collection of diverse cells, and no two brains are the same, cellularly speaking. Those are the prevailing conclusions of an onslaught of 21 papers published online October 12 in Science, Science Advances and Science Translational Medicine. The results just start to scratch the surface of understanding the mysteries of the brain. Still, they provide the most intimate look yet at the cells that build the brain, and offer clues about how the brain enables thoughts, actions and memories. The collection of data may also guide researchers in their hunt for the causes of brain disorders such as schizophrenia, Alzheimer’s disease and depression. The new brain map is a result of a coordinated international research effort called the National Institutes of Health’s Brain Initiative Cell Census Network, or BICCN, which ramped up in 2017. Many of the studies in the collection are based on a powerful technology called single-cell genomics. The method reveals which genes are active inside of a single cell, information that provides clues about the cell’s identity and job. As part of the BICCN, researchers examined all sorts of brains. One project detailed the cells in small pieces of live brain tissue taken from 75 people undergoing surgery for tumors or epilepsy, an approach that’s been used on smaller scales before (SN: 8/7/19). Another looked at samples taken from the brains of 17 deceased children. Still another looked at brain tissue from seven people, seven chimpanzees, four gorillas, three rhesus macaques and three marmosets. © Society for Science & the Public 2000–2023.

Keyword: Development of the Brain; Brain imaging
Link ID: 28962 - Posted: 10.14.2023

By Mark Johnson Using a host of high-tech tools to simulate brain development in a lab dish, Stanford University researchers have discovered several dozen genes that interfere with crucial steps in the process and may lead to autism, a spectrum of disorders that affects about one in every 36 Americans, impairing their ability to communicate and interact with others. The results of a decade of work, the findings published in the journal Nature may one day pave the way for scientists to design treatments that allow these phases of brain development to proceed unimpaired. The study delves into a 20-year-old theory that suggests one cause of autism may be a disruption of the delicate balance between two types of nerve cells found in the brain’s cerebral cortex, the area responsible for higher-level processes such as thought, emotion, decision-making and language. Some nerve cells in this region of the brain excite other nerve cells, encouraging them to fire; other cells, called interneurons, do the opposite. Too much excitation can impair focus in the brain and cause epilepsy, a seizure disorder that is more common in people with autism than in the general population. Scientists therefore believe a proper balance requires more of the inhibiting interneurons. In the developing fetus, these nerve cells start out deep in the brain in a region called the subpallium, then migrate slowly to the cerebral cortex. The process begins mid-gestation and ends in the infant’s second year of life, said Sergiu Pasca, a Stanford University professor of psychiatry and behavioral sciences who led the study. Pasca’s team, which included researchers from the University of California at San Francisco and the Icahn School of Medicine at Mount Sinai, tested 425 genes that have been linked to neurodevelopmental disorders to determine which ones interfere with the generation and migration of interneurons. Genes linked to autism were among those identified in the study. “What’s really cool about this paper is that autism is a collection of different behaviors, but we don’t have [an] understanding of how those behaviors are connected to differences in the brain,” said James McPartland, a professor of child psychiatry and psychology at the Yale School of Medicine, who was not involved in the study. The new work advances research into autism by “beginning to create a fundamental understanding of the building blocks of brain development,” he said.

Keyword: Autism; Genes & Behavior
Link ID: 28947 - Posted: 10.07.2023

Jon Hamilton A team of researchers has developed a new way to study how genes may cause autism and other neurodevelopmental disorders: by growing tiny brain-like structures in the lab and tweaking their DNA. These "assembloids," described in the journal Nature, could one day help researchers develop targeted treatments for autism spectrum disorder, intellectual disability, schizophrenia, and epilepsy. "This really accelerates our effort to try to understand the biology of psychiatric disorders," says Dr. Sergiu Pașca, a professor of psychiatry and behavioral sciences at Stanford University and an author of the study. The research suggests that someday "we'll be able to predict which pathways we can target to intervene" and prevent these disorders, adds Kristen Brennand, a professor of psychiatry at Yale who was not involved in the work. The study comes after decades of work identifying hundreds of genes that are associated with autism and other neurodevelopmental disorders. But scientists still don't know how problems with these genes alter the brain. "The challenge now is to figure out what they're actually doing, how disruptions in these genes are actually causing disease," Pașca says. "And that has been really difficult." For ethical reasons, scientists can't just edit a person's genes to see what happens. They can experiment on animal brains, but lab animals like rodents don't really develop anything that looks like autism or schizophrenia. So Pașca and a team of scientists tried a different approach, which they detailed in their new paper. The team did a series of experiments using tiny clumps of human brain cells called brain organoids. These clumps will grow for a year or more in the lab, gradually organizing their cells much the way a developing brain would. And by exposing an organoid to certain growth factors, scientists can coax it into resembling tissue found in brain areas including the cortex and hippocampus. © 2023 npr

Keyword: Epilepsy; Autism
Link ID: 28940 - Posted: 10.03.2023

Sara Reardon Scientists have identified two types of brain cell linked to a reduced risk of dementia in older people — even those who have brain abnormalities that are hallmarks of Alzheimer’s disease1. The finding could eventually lead to new ways to protect these cells before they die. The results were published in Cell on 28 September. The most widely held theory about Alzheimer’s attributes the disease to a build-up of sticky amyloid proteins in the brain. This leads to clump-like ‘plaques’ of amyloid that slowly kill neurons and eventually destroy memory and cognitive ability. But not everyone who develops cognitive impairment late in life has amyloid clumps in their brain, and not everyone with amyloid accumulation develops Alzheimer’s. Neurobiologist Hansruedi Mathys at the University of Pittsburgh School of Medicine in Pennsylvania and neuroscientist Li-Huei Tsai and computer scientist Manolis Kellis at the Massachusetts Institute of Technology in Cambridge and their colleagues decided to investigate this disconnect. To do so, they used data from a massive study that tracks cognitive and motor skills in thousands of people throughout old age. The researchers examined tissue samples from 427 brains from participants who had died. Some of those participants had dementia typical of advanced Alzheimer’s disease, some had mild cognitive impairment and the remainder had no sign of impairment. The researchers isolated cells from each participant’s prefrontal cortex, the region involved in higher brain function. To classify the cells, they sequenced all the active genes in each one. This allowed them to create an atlas of the brain showing where the different cell types occur. The scientists identified two key cell types that had a specific genetic marker. One had active genes coding for reelin, a protein associated with brain disorders such as schizophrenia, and the other had active genes that code for somatostatin, a hormone that regulates processes throughout the body. © 2023 Springer Nature Limited

Keyword: Alzheimers; Genes & Behavior
Link ID: 28938 - Posted: 09.29.2023

COMIC: When, why and how did neurons first evolve? Scientists are piecing together the ancient story. By Tim Vernimmen Illustrated by Maki Naro 09.14.2023 © 2023 Annual Reviews

Keyword: Evolution; Development of the Brain
Link ID: 28920 - Posted: 09.21.2023

By Janet Lee Doing puzzles, playing memory-boosting games, taking classes and reading are activities that we often turn to for help keeping our brains sharp. But research is showing that what you eat, how often you exercise and the type of exercise you do can help lower your risk of dementia to a greater extent than previously thought. Live well every day with tips and guidance on food, fitness and mental health, delivered to your inbox every Thursday. Although more studies are needed, “there’s a lot of data that suggests exercise and diet are good for the brain and can prevent or help slow down” cognitive changes, says Jeffrey Burns, co-director of the University of Kansas Alzheimer’s Disease Research Center in Fairway. And living a healthy lifestyle can produce brain benefits no matter what your age. The big diet picture If you’re already eating in a way that protects your heart — plenty of whole grains, vegetables, and fruit, and little saturated fat, sodium and ultra-processed “junk” foods — there’s good news: You’re also protecting your brain. A healthy cardiovascular system keeps blood vessels open, allowing good blood flow to the brain and reducing the risk of high blood pressure, stroke and dementia. Research suggests that two specific dietary approaches — the Mediterranean diet and the MIND diet (the Mediterranean-DASH Intervention for Neurodegenerative Delay, essentially a combo of two heart-healthy eating plans) — may help stave off cognitive decline. Both diets rely on eating mostly plant foods (fruits, vegetables, whole grains, beans, nuts), olive oil, fish and poultry. The main difference between the two is that the MIND diet emphasizes specific fruits and vegetables, such as berries and leafy greens. Studies show that people who most closely follow either diet have a reduced risk of dementia compared with those who don’t. For example, people eating the Mediterranean way had a 23 percent lower risk of dementia in a nine-year study of more than 60,000 men and women published this year in BMC Medicine.

Keyword: Alzheimers
Link ID: 28915 - Posted: 09.21.2023

By Jacqueline Howard and Deidre McPhillips, Most families of children with autism may face long wait times to diagnose their child with the disorder, and once a diagnosis is made, it sometimes may not be definitive. But now, two studies released Tuesday suggest that a recently developed eye-tracking tool could help clinicians diagnose children as young as 16 months with autism – and with more certainty. Kids’ developmental disability diagnoses became more common during pandemic, but autism rates held steady, CDC report says “This is not a tool to replace expert clinicians,” said Warren Jones, director of research at the Marcus Autism Center at Children’s Healthcare of Atlanta and Nien Distinguished Chair in Autism at Emory University School of Medicine, who was an author on both studies. Rather, he said, the hope with this eye-tracking technology is that “by providing objective measurements that objectively measure the same thing in each child,” it can help inform the diagnostic process. The tool, called EarliPoint Evaluation, is cleared by the US Food and Drug Administration to help clinicians diagnose and assess autism, according to the researchers. Traditionally, children are diagnosed with autism based on a clinician’s assessment of their developmental history, behaviors and parents’ reports. Evaluations can take hours, and some subtle behaviors associated with autism may be missed, especially among younger children. “Typically, the way we diagnose autism is by rating our impressions,” said Whitney Guthrie, a clinical psychologist and scientist at the Children’s Hospital of Philadelphia’s Center for Autism Research. She was not involved in the new studies, but her research focuses on early diagnosis of autism.

Keyword: Autism; Schizophrenia
Link ID: 28904 - Posted: 09.13.2023

By Claudia López Lloreda Cells hidden in the skull may point to a way to detect, diagnose and treat inflamed brains. A detailed look at the skull reveals that bone marrow cells there change and are recruited to the brain after injury, possibly traveling through tiny channels connecting the skull and the outer protective layer of the brain. Paired with the discovery that inflammation in the skull is disease-specific, these new findings collectively suggest the skull’s marrow could serve as a target to track and potentially treat neurological disorders involving brain inflammation, researchers report August 9 in Cell. Immune cells that infiltrate the central nervous system during many diseases and neuronal injury can wreak havoc by flooding the brain with damaging molecules. This influx of immune cells causes inflammation in the brain and spinal cord and can contribute to diseases like multiple sclerosis (SN: 11/26/19). Detecting and dampening this reaction has been an extensive field of research. With this new work, the skull, “something that has been considered as just protective, suddenly becomes a very active site of interaction with the brain, not only responding to brain diseases, but also changing itself in response to brain diseases,” says Gerd Meyer zu Hörste, a neurologist at University of Münster in Germany who was not involved in the study. Ali Ertürk of the Helmholtz Center in Munich and colleagues discovered this potential role for the skull while probing the idea that the cells in skull marrow might behave differently from those in other bones. Ertürk’s team compared the genetic activity of cells in mice skull marrow, and the proteins those cells made, with those in the rodent’s humerus, femur and four other bones, along with the meninges, the protective membranes between the skull and the brain. © Society for Science & the Public 2000–2023.

Keyword: Alzheimers; Multiple Sclerosis
Link ID: 28898 - Posted: 09.07.2023

Diana Kwon Santiago Ramón y Cajal revolutionized neurobiology in the late nineteenth century with his exquisitely detailed illustrations of neural tissues. Created through years of meticulous microscopy work, the Spanish physician-scientist’s drawings revealed the unique cellular morphology of the brain. “With Cajal’s work, we saw that the cells of the brain don’t look like the cells of every other part of the body — they have incredible morphologies that you just don’t see elsewhere,” says Evan Macosko, a neuroscientist at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts. Ramón y Cajal’s drawings provided one of the first clues that the keys to understanding how the brain governs its many functions, from regulating blood pressure and sleep to controlling cognition and mood, might lie at the cellular level. Still, when it comes it comes to the brain, crucial information remained — and indeed, remains — missing. “In order to have a fundamental understanding of the brain, we really need to know how many different types of cells there are, how are they organized, and how they interact with each other,” says Xiaowei Zhuang, a biophysicist at Harvard University in Cambridge. What neuroscientists require, Zhuang explains, is a way to systematically identify and map the many categories of brain cells. Now researchers are closing in on such a resource, at least in mice. By combining high-throughput single-cell RNA sequencing with spatial transcriptomics — methods for determining which genes are expressed in individual cells, and where those cells are located — they are creating some of the most comprehensive atlases of the mouse brain so far. The crucial next steps will be working out what these molecularly defined cell types do, and bringing the various brain maps together to create a unified resource that the broader neuroscience community can use. © 2023 Springer Nature Limited

Keyword: Brain imaging; Development of the Brain
Link ID: 28880 - Posted: 08.24.2023

By Lauren Leffer When a nematode wriggles around a petri dish, what’s going on inside a tiny roundworm’s even tinier brain? Neuroscientists now have a more detailed answer to that question than ever before. As with any experimental animal, from a mouse to a monkey, the answers may hold clues about the contents of more complex creatures’ noggin, including what resides in the neural circuitry of our own head. A new brain “atlas” and computer model, published in Cell on Monday, lays out the connections between the actions of the nematode species Caenorhabditis elegans and this model organism’s individual brain cells. With the findings, researchers can now observe a C. elegans worm feeding or moving in a particular way and infer activity patterns for many of the animal’s behaviors in its specific neurons. Through establishing those brain-behavior links in a humble roundworm, neuroscientists are one step closer to understanding how all sorts of animal brains, even potentially human ones, encode action. “I think this is really nice work,” says Andrew Leifer, a neuroscientist and physicist who studies nematode brains at Princeton University and was not involved in the new research. “One of the most exciting reasons to study how a worm brain works is because it holds the promise of being able to understand how any brain generates behavior,” he says. “What we find in the worm forms hypotheses to look for in other organisms.” Biologists have been drawn to the elegant simplicity of nematode biology for many decades. South African biologist Sydney Brenner received a Nobel Prize in Physiology or Medicine in 2002 for pioneering work that enabled C. elegans to become an experimental animal for the study of cell maturation and organ development. C. elegans was the first multicellular organism to have its entire genome and nervous system mapped. The first neural map, or “connectome,” of a C. elegans brain was published in 1986. In that research, scientists hand drew connections using colored pencils and charted each of the 302 neurons and approximately 5,000 synapses inside the one-millimeter-long animal’s transparent body. Since then a subdiscipline of neuroscience has emerged—one dedicated to plotting out the brains of increasingly complex organisms. Scientists have compiled many more nematode connectomes, as well as brain maps of a marine annelid worm, a tadpole, a maggot and an adult fruit fly. Yet these maps simply serve as a snapshot in time of a single animal. They can tell us a lot about brain structure but little about how behaviors relate to that structure. © 2023 Scientific American

Keyword: Brain imaging; Development of the Brain
Link ID: 28879 - Posted: 08.24.2023

by Calli McMurray One of the co-directors of a now-shuttered Maryland psychology clinic implicated in 18 paper retractions has retired, Spectrum has learned. Prior to her retirement, Clara Hill was professor of psychology at the University of Maryland in College Park. Headshot of Clara Hill. Recent retirement: Clara Hill retired from the University of Maryland in the midst of 18 paper retractions after a 49-year career. Starting on 1 June, the American Psychological Association (APA) retracted 11 papers by Hill and her university colleagues Dennis Kivlighan, Jr. and Charles Gelso over issues with obtaining participant consent. The publisher plans to retract six more papers by the end of the year, according to an APA representative. On 13 August, Taylor & Francis retracted an additional paper led solely by Hill. The research was conducted at the Maryland Psychotherapy Clinic and Research Lab, where Hill, Kivlighan and Gelso were co-directors. The clinic had shut down as of 1 June. When asked about the circumstances surrounding Hill’s retirement, a university spokesperson told Spectrum in an email, “Dr. Clara Hill retired from UMD effective July 1, 2023.” After Spectrum asked again about the circumstances, a spokesperson replied, “This is all we’ll have for you on the faculty member’s retirement — thanks!” Hill worked at the university for 49 years. As of 1 August, Hill’s faculty page did not mention her retirement. By 14 August, her position had been amended to “Professor (Retired),” and a notice of her retirement had been added to the beginning of her biography. Spectrum left two voicemails on Hill’s university office phone and emailed her university address with requests for comment but did not hear back. The 11 papers retracted by the APA appeared in the Journal of Counseling Psychology, Dreaming and Psychotherapy. The additional retractions will come from the same titles, according to an APA representative. Hill conducted all 11 studies, whereas Kivlighan and Gelso conducted 10 and 6, respectively. © 2023 Simons Foundation

Keyword: Autism
Link ID: 28877 - Posted: 08.24.2023

Saima May Sidik A protein involved in wound healing can improve learning and memory in ageing mice1. Platelet factor 4 (PF4) has long been known for its role in promoting blood clotting and sealing broken blood vessels. Now, researchers are wondering whether this signalling molecule could be used to treat age-related cognitive disorders such as Alzheimer’s disease. “The therapeutic possibilities are very exciting,” says geneticist and anti-ageing scientist David Sinclair at Harvard University in Boston, Massachusetts, who was not involved in the research. The study was published on 16 August in Nature. Young blood, old brains About a decade ago, scientists discovered that blood from young mice could restore youthful properties, including learning abilities, in older mice2,3. The idea captivated Saul Villeda, a neuroscientist at the University of California, San Francisco, and a co-author of the new study. He and his colleagues have since been trying to identify the components of blood that cause this rejuvenation. Several lines of evidence suggested that PF4 might be one of these components, including the fact that young mice have higher levels of this molecule in their blood than do older mice. Villeda and his colleagues tried injecting PF4 into aged mice without including other blood components. The researchers found that the ratios of various types of immune cell shifted to become more similar to what is typically seen in younger mice. Some immune cells also reverted to a more youthful pattern of gene expression. Although PF4 was not able to cross the blood–brain barrier, its effects on the immune system also led to changes in the brain, probably through indirect mechanisms. Old mice that received doses of PF4 showed decreases in damaging inflammation in the hippocampus — a part of the brain that’s particularly vulnerable to the effects of ageing. They also showed increases in the levels of molecules that promote synaptic plasticity (the capacity to alter the strength of connections between nerve cells). © 2023 Springer Nature Limited

Keyword: Development of the Brain
Link ID: 28874 - Posted: 08.19.2023

by Giorgia Guglielmi Mice with a mutation that boosts the activity of the autism-linked protein UBE3A show an array of behaviors reminiscent of the condition, a new study finds. The behaviors differ depending on whether the animals inherit the mutation from their mother or their father, the work also reveals. The results add to mounting evidence that hyperactive UBE3A leads to autism. Duplications of the chromosomal region that includes UBE3A have been associated with autism, whereas deletions and mutations that destroy the gene’s function are known to cause Angelman syndrome, which is characterized by developmental delay, seizures, lack of speech, a cheerful demeanor and, often, autism. “UBE3A is on a lot of clinicians’ radar because it is well known to be causative for Angelman syndrome when mutated or deleted,” says lead investigator Mark Zylka, professor of cell biology and physiology at the University of North Carolina at Chapel Hill. “What our study shows is that just because you have a mutation in UBE3A, it doesn’t mean that it’s going to be Angelman syndrome.” In the cell, UBE3A is involved in the degradation of proteins, and “gain-of-function” mutations — which send the UBE3A protein into overdrive — result in enhanced degradation of its targets, including UBE3A itself. Studying the effects of these mutations could provide insight into how they affect brain development and suggest targets for therapies, says study investigator Jason Yi, assistant professor of neuroscience at Washington University in St. Louis, Missouri. Gain-of-function mutations in UBE3A can disrupt early brain development and may contribute to neurodevelopmental conditions that are distinct from Angelman syndrome, Yi and Zylka have shown in previous studies. One of the mutations they analyzed had been found in an autistic child, so the team used CRISPR to create mice with this mutation. © 2023 Simons Foundation

Keyword: Autism
Link ID: 28857 - Posted: 07.27.2023

Lilly Tozer A study that followed thousands of people over 25 years has identified proteins linked to the development of dementia if their levels are unbalanced during middle age. The findings, published in Science Translational Medicine on 19 July1, could contribute to the development of new diagnostic tests, or even treatments, for dementia-causing diseases. Most of the proteins have functions unrelated to the brain. “We’re seeing so much involvement of the peripheral biology decades before the typical onset of dementia,” says study author Keenan Walker, a neuroscientist at the US National Institute on Aging in Bethesda, Maryland. Equipped with blood samples from more than 10,000 participants, Walker and his colleagues questioned whether they could find predictors of dementia years before its onset by looking at a person’s proteome — the collection of all the proteins expressed throughout the body. They searched for any signs of dysregulation — when proteins are at levels much higher or lower than normal. The samples were collected as part of an ongoing study that began in 1987. Participants returned for examination six times over three decades, and during this time, around 1 in 5 of them developed dementia. The researchers found 32 proteins that, if dysregulated in people aged 45 to 60, were strongly associated with an elevated chance of developing dementia in later life. It is unclear how exactly these proteins might be involved in the disease, but the link is “highly unlikely to be due to just chance alone”, says Walker © 2023 Springer Nature Limited

Keyword: Alzheimers
Link ID: 28856 - Posted: 07.22.2023

By Pam Belluck Treating Alzheimer’s patients as early as possible — when symptoms and brain pathology are mildest — provides a better chance of slowing cognitive decline, a large study of an experimental Alzheimer’s drug presented Monday suggests. The study of 1,736 patients reported that the drug, donanemab, made by Eli Lilly, can modestly slow the progression of memory and thinking problems in early stages of Alzheimer’s, and that the slowing was greatest for early-stage patients when they had less of a protein that creates tangles in the brain. For people at that earlier stage, donanemab appeared to slow decline in memory and thinking by about four and a half to seven and a half months over an 18-month period compared with those taking a placebo, according to the study, published in the journal JAMA. Among people with less of the protein, called tau, slowing was most pronounced in those younger than 75 and those who did not yet have Alzheimer’s but had a pre-Alzheimer’s condition called mild cognitive impairment, according to data presented Monday at the Alzheimer’s Association International Conference in Amsterdam. “The earlier you can get in there, the more you can impact it before they’ve already declined and they’re on this fast slope,” Dr. Daniel Skovronsky, Eli Lilly’s chief medical and scientific officer, said in an interview. “No matter how you cut the data — earlier, younger, milder, less pathology — every time, it just looks like early diagnosis and early intervention are the key to managing this disease,” he added. The findings and the recent approval of another drug that modestly slows decline in the early stages of Alzheimer’s, Leqembi, signal a potentially promising turn in the long, rocky path toward finding effective medications for Alzheimer’s, a brutal disease that plagues more than six million Americans. Donanemab is currently being considered for approval by the Food and Drug Administration. © 2023 The New York Times Company

Keyword: Alzheimers
Link ID: 28852 - Posted: 07.19.2023

Nicola Davis Science correspondent Taking part in activities such as chess, writing a journal, or educational classes in older age may help to reduce the risk of dementia, a study has suggested. According to the World Health Organization, more than 55 million people have the disease worldwide, most of them older people. However experts have long emphasised that dementia is not an inevitable part of ageing, with being active, eating well and avoiding smoking among the lifestyle choices that can reduce risk. Now researchers have revealed fresh evidence that challenging the brain could also be beneficial. Writing in the journal Jama Network Open, researchers in the US and Australia report how they used data from the Australian Aspree Longitudinal Study of Older Persons covering the period from 1 March 2010 to 30 November 2020. Participants in the study were over the age of 70, did not have a major cognitive impairment or cardiovascular disease when recruited between 2010 and 2014, and were assessed for dementia through regular study visits. In the first year, participants were asked about their social networks. They were also questioned on whether they undertook certain leisure activities or trips out to venues such as galleries or restaurants, and how frequently: never, rarely, sometimes, often or always. The team analysed data from 10,318 participants, taking into account factors such as age, sex, smoking status, education, socioeconomic status, and whether participants had other diseases such as diabetes. The results reveal that for activities such as writing letters or journals, taking educational classes or using a computer, increasing the frequency of participation by one category, for example from “sometimes” to “often”, was associated with an 11% drop in the risk of developing dementia over a 10-year period. Similarly, increased frequency of activities such as card games, chess or puzzle-solving was associated with a 9% reduction in dementia risk. © 2023 Guardian News & Media Limited

Keyword: Alzheimers; Learning & Memory
Link ID: 28851 - Posted: 07.19.2023

Lilly Tozer Injecting ageing monkeys with a ‘longevity factor’ protein can improve their cognitive function, a study reveals. The findings, published on 3 July in Nature Aging1, could lead to new treatments for neurodegenerative diseases. It is the first time that restoring levels of klotho — a naturally occurring protein that declines in our bodies with age — has been shown to improve cognition in a primate. Previous research on mice had shown that injections of klotho can extend the animals’ lives and increases synaptic plasticity2 — the capacity to control communication between neurons, at junctions called synapses. “Given the close genetic and physiological parallels between primates and humans, this could suggest potential applications for treating human cognitive disorders,” says Marc Busche, a neurologist at the UK Dementia Research Institute group at University College London. The protein is named after the Greek goddess Clotho, one of the Fates, who spins the thread of life. The study involved testing the cognitive abilities of old rhesus macaques (Macaca mulatta), aged around 22 years on average, before and after a single injection of klotho. To do this, researchers used a behavioural experiment to test for spatial memory: the monkeys had to remember the location of an edible treat, placed in one of several wells by the investigator, after it was hidden from them. Study co-author Dena Dubal, a physician-researcher at the University of California, San Francisco, compares the test to recalling where you left your car in a car park, or remembering a sequence of numbers a couple of minutes after hearing it. Such tasks become harder with age. The monkeys performed significantly better in these tests after receiving klotho — before the injections they identified the correct wells around 45% of the time, compared with around 60% of the time after injection. The improvement was sustained for at least two weeks. Unlike in previous studies involving mice, relatively low doses of klotho were effective. This adds an element of complexity to the findings, which suggests a more nuanced mode of actions than was previously thought, Busche says. © 2023 Springer Nature Limited

Keyword: Learning & Memory; Development of the Brain
Link ID: 28847 - Posted: 07.06.2023